While research on cancer is gaining popularity especially among research scientists and pharmaceutical companies, success has become elusive when it comes to developing effective cancer drugs and therapies. However, Seattle Genetics under the leadership of its cofounder Clay Siegall has made significant progress in developing an effective alternative and innovative cancer therapy. In 2011, the company scored a milestone following the approval of its conjugate therapy, Adcetris by the U.S. Food and Drug Administration (FDA). The drug is currently being used in over 60 countries. Adcetris is the first in a long list of drugs the company hopes to introduce into the market in the coming years. Through partnership with numerous industry players such as GlaxoSmithKline and Bayer, Seattle Genetics aims at introducing a further 20 drugs into the market.
However, the landmark achievement was not solely hinged on the company’s high profile partnerships. Clay Siegall who serves as the directors, board chairman, president and chief executive officer at Seattle Genetics has played a critical role in the success. He has helped the company raise over a billion dollars in capital to help in financing the company’s research initiatives.
Clay Siegall’s Fight against Cancer: A Passion Born Out of Personal Experience
After witnessing a close family member battle cancer especially the traumatizing pain associated with the conventional treatments, Clay Siegall was inspired to come up with new and better cancer alternative treatment options. At the time, he was a student at the University of Maryland studying Bachelor of Science in Zoology. He would later join the George Washington University for his Doctor of Philosophy degree in Genetics. He has directed efforts towards greater understanding of cancer and finding an alternative cure that with fewer and less severe side effects than the conventional treatment options available.
He has authored dozens of articles on cancer in addition to the numerous inventions he has come up with. Even before cofounding Seattle Genetics in 1998, Clay Siegall dedicated his professional career as a research scientist for organizations dedicated to cancer research including Cancer Research Institute. In addition to his current roles at Seattle Genetics, Clay Siegall also serves as a member of the board of directors at Ultragenyx Pharmaceutical among other pharmaceutical companies.